By 2030, it is anticipated that the Romania Dermatology drugs market will reach a value of $xx Mn from $49.3 Mn in 2022, growing at a CAGR of xx% during 2022-2030. The market is primarily dominated by local players such as Ropharma, Terapia, and Antibiotics. The market is driven by government regulations, the prevalence of dermatological disease, and improved health indicators in the country. The dermatology drug market in Romania is segmented by drug class, drug type, prescription mode, indication, route of administration, end-user, and distribution channEL
By 2030, it is anticipated that the Romania Dermatology drugs market will reach a value of $xx Mn from $49.3 Mn in 2022, growing at a CAGR of xx% during 2022-2030.
Acne, eczema, psoriasis, and rosacea are some of the most typical skin issues in Romania. A sizable portion of people is affected by acne, especially adolescents and young adults. In Romania, 10–20% of children and 1-3% of adults suffer from atopic dermatitis (eczema). Approximately 2-3% of Romanians suffer from psoriasis. Rosacea affects an estimated 1–10% of adults in Romania.
In Romania, skin cancer is one of the most prevalent cancers, with an estimated 10,000 new cases being identified each year. Romania spent more on government healthcare than other Eastern European nations like Russia, Moldova, and Ukraine, accounting for 78.5% of the overall budget.
Market Growth Drivers
The development of the dermatology drugs market is anticipated to pick up steam in the upcoming years as a result of the Romanian government's initiatives to modernize and enhance the nation's healthcare system and rising public awareness of skin diseases. Additionally, the growing aging population and rising incidence of skin cancer are also contributing factors to the market's growth. Romania had some of the lowest healthcare spending per person in the EU in 2021, at $16.7 Bn, or $872.3 per person, and 5.9% of GDP. As a result, more businesses will enter the market and offer their products at reasonable prices.
Market Restraints
Due to problems like the claw-back tax and pricing concessions required by the National Health Insurance House (CNAS), many companies have recently been forced to withdraw their goods from the Romanian market, lay off employees, or scale back operations there.
Key Players
The National Medicines Agency (NMA), also referred to as the National Agency for Medicines and Medical Devices, is the regulatory organization in charge of regulating the approval and distribution of dermatology medications in Romania. The NMA is in charge of assessing the efficacy and safety of medical products, such as prescription and over-the-counter medicines and making sure they comply with Romanian and EU regulations.
The National Health Insurance House (Casa Nationala de Asigurari de Sanatate, CNAS), which is in charge of managing the nation's national health insurance system, oversees the reimbursement of dermatology medications in Romania. A drug must fulfill certain requirements, such as being deemed necessary for the treatment of a particular condition, being cost-effective, and being approved for use in Romania, in order to be eligible for reimbursement.
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
The Dermatology Drugs Market is segmented as mentioned below
By Disease (Revenue, USD Billion):
By Route Of Administration (Revenue, USD Billion):
By Distribution Channel (Revenue, USD Billion):
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.